Skip to main content

Table 5 Investigator assessment of best clinical response a

From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Best clinical response

All patients

(N = 46), n (%)

CRb

2 (4)

PR

2 (4)

SD

13 (28)

PD

26 (57)

Unknownc

3 (7)

  1. aPer response criteria in Cheson et al. [11].
  2. bBoth CRs were confirmed.
  3. cNo post-baseline evaluations available.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us